GSK Gears Up To Fight NICE On Benlysta Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.
You may also be interested in...
GSK’s Benlysta Discount Isn’t Big Enough To Avoid NICE Rejection
NICE says GSK did not adequately compare its lupus drug belimumab to Roche’s Mab Thera (rituximab). While the firm and partner Human Genome Sciences did offer data that appeared to show an advantage, the problem is that the positive results were more prevalent in a patient population that did not broadly reflect the make-up of the U.K., NICE said.
Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta
Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.
Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta
Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.